Liquidia Technologies has announced results from two studies of inhalation formulations created using the company’s PRINT (Particle Replication In Non-Wetting Templates) particle engineering technology. One study, published in the 2012 issue of the Journal of Drug Delivery, compared aerodynamic properties of PRINT-zanamivir inhalation powder to Relenza; the other, presented at RDD, investigated properties of an excipient-free PRINT-itraconazole formulation to jet-milled particles.
Liquidia Executive Director of Research Benjamin Maynor commented, “It is understood that particle size and shape can play a significant role in the way an aerosolized medicine is distributed throughout the lung, but until now, complete control of these particle characteristics has not been possible. The PRINT platform allows Liquidia and its partner companies to rapidly design and manufacture a diverse range of precisely engineered therapeutic particles that can be used for the unprecedented exploration of new product opportunities in the treatment of respiratory disease.”
“By leveraging precise fabrication techniques of the semiconductor industry, Liquidia has the unique ability to address persisting unmet needs in respiratory medicine and other therapeutic areas. The growing body of data supporting the benefits of PRINT technology highlights the exciting potential for Liquidia and its partners to develop novel pulmonary products, including biologics and combined therapeutics, with significantly increased aerosol performance, controlled release, reduced excipient load, and/or targeted delivery,” added Liquidia VP of Development Kyle Chenet.
Read the Liquidia press release.
Read the Journal of Drug Delivery article.
